Our findings suggest that paclitaxel treatment combined with inhibition of autophagy might be a potentially more effective chemotherapeutic approach for FLCN-deficient renal cancer and BHD-related kidney tumors. The gene discussed is FLCN; the disease is renal carcinoma.